Medicare AdvantageCoverageHigh impact
[Virginia] Carelon Medical Benefits Management Clinical Appropriateness Guidelines updates
Anthem BCBS·VA · Oncology, Pathology, Hematology +2 more·Provider Bulletin
Effective date
Nov 15, 2026
We identified it
Aug 2, 2026
Summary
Carelon (Anthem Medicare Advantage Virginia) updated clinical appropriateness guidelines effective November 15, 2026, expanding coverage for genetic/molecular testing in multiple cancer types (breast, prostate, lung, thyroid, etc.), hematologic malignancies, and orthopedic procedures. Key changes include new drug therapies triggering testing requirements (imlunestrant, niraparib), broadened indications for existing tests, and standardized 12-week conservative management requirements for joint surgery. Practices must update prior authorization criteria, clinical documentation templates, and testing protocols to align with expanded coverage.
Action Required
Before November 15, 2026: (1) ONCOLOGY/PATHOLOGY TEAMS: Update prior authorization workflows to reflect expanded genetic testing coverage for breast cancer (stages IIB-IIIC, recurrent, locally advanced), prostate cancer (metastatic, all clinical indications), lung cancer (stage IIIB+), thyroid cancer (anaplastic, medullary, metastatic), and hematologic malignancies. Remove prior auth denials for: ESR1 mutation testing with imlunestrant; niraparib with PARP inhibitor therapy; targeted RNA fusion analysis via NGS; HRD testing for maintenance therapy in ovarian cancer; MSI/multigene panel testing in cancers of unknown origin. (2) ORTHOPEDIC TEAMS: Update authorization requirements to standardize conservative management duration to 12 weeks across all joint procedures (shoulder/hip/knee arthroplasty, arthroscopy, meniscal allograft, osteochondral grafts). Remove prior auth for bone growth stimulation devices (electrical/ultrasound) for appendicular skeleton per new criteria. Require 12-week interval documentation between arthroscopy and arthroplasty procedures. (3) CLINICAL DOCUMENTATION: Update EMR templates and encounter forms to capture: cancer stage (AJCC for breast), therapy type (document imlunestrant, niraparib use), prior treatment response, and ADL functional impact for orthopedic cases. (4) BILLING TEAMS: Review claims submitted September 2026-November 15, 2026 for genetic testing and orthopedic procedures; resubmit previously denied claims that now meet expanded coverage criteria. (5) PROVIDERS: Stop ordering non-covered tests effective Nov 15: RNA fusion/expression analysis using ctRNA, ctHPV DNA for oropharyngeal carcinoma surveillance, breast cancer recurrence testing, NIFTP somatic testing, WES/WGS/WTA analyses. Consequences: Claims for expanded genetic testing and orthopedic procedures submitted under old guidelines may be denied; failure to document conservative management duration will trigger arthroscopy/arthroplasty denials.